Taken together, co-treatment of Apigenin with PI3Ki GDC-0941 may increase therapeutic efficacy of RAI for invasive fronts of thyroid cancer, by utilizing two distinct mechanisms—by increasing NIS protein level to counteract TGF-β's effect on NIS reduction and by decreasing RAI efflux rate, respectively. This evidence concerns the gene SLC5A5 and thyroid gland carcinoma.